Literature DB >> 9541082

Willingness to pay for hormone replacement therapy.

N Zethraeus1.   

Abstract

This study addresses the question of willingness to pay (WTP) for hormone replacement therapy (HRT) in order to alleviate menopausal symptoms. The woman obtains utility from consumption of goods and health. The purchase of a treatment is represented as a shift in the health production function during the treatment period. The mean WTP for the HRT is estimated using a parametric and a non-parametric method. The mean WTP based on these two methods is similar in both cases and amounts to about SEK 40000 per year. Further, it is shown that the mean WTP is above the mean treatment cost of HRT. Finally, the implied WTP per gained quality adjusted life year (QALY) is estimated at about SEK 120000 and SEK 160000 based on the rating scale (RS) and time trade-off (TTO) methods, respectively.

Entities:  

Mesh:

Year:  1998        PMID: 9541082     DOI: 10.1002/(sici)1099-1050(199802)7:1<31::aid-hec316>3.0.co;2-7

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  11 in total

Review 1.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Determinants of willingness to pay for a new therapy in a sample of menopausal-aged women.

Authors:  Andrej Rasch; Jan-Marc Hodek; Claus Runge; Wolfgang Greiner
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UK.

Authors:  J M Plumb; J F Guest
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

4.  Willingness to pay for inhaled insulin: a contingent valuation approach.

Authors:  Hamid Sadri; Linda D MacKeigan; Lawrence A Leiter; Thomas R Einarson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.

Authors:  O Ström; F Borgström; S S Sen; S Boonen; P Haentjens; O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2007-02-28       Impact factor: 4.507

6.  Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.

Authors:  Christian R C Kouakou; Thomas G Poder
Journal:  Eur J Health Econ       Date:  2021-08-21

7.  Consumer preference for dinoprostone vaginal gel using stated preference discrete choice modelling.

Authors:  Susan Taylor; Carol Armour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 8.  A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?

Authors:  Khachapon Nimdet; Nathorn Chaiyakunapruk; Kittaya Vichansavakul; Surachat Ngorsuraches
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

9.  Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.

Authors:  Khachapon Nimdet; Surachat Ngorsuraches
Journal:  BMJ Open       Date:  2015-10-05       Impact factor: 2.692

10.  Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

Authors:  Montarat Thavorncharoensap; Yot Teerawattananon; Sirin Natanant; Wantanee Kulpeng; Jomkwan Yothasamut; Pitsaphun Werayingyong
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.